NIH R01 · 2024
Disregard of genetically-linked biological variation in the design and interpretation of clinical trials of marine omega-3 (n-3) highly unsaturated fatty acid (HUFA) supplementation and specifically limited inclusion of individuals carrying high-activity fatty-acid-desaturase (FADS1) alleles may have masked potential health benefits of individuals at elevated risk for cardiovascular and other chronic diseases. Our work over the past decade has revealed that genetic variation throughout the FADS gene cluster, and the resulting allele-frequency differences among population strata, are significant drivers of the effectiveness of n-3 HUFA supplementation. FADS1 are the rate-limiting steps in…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.